ORIGINAL RESEARCH article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1627904
This article is part of the Research TopicInterdisciplinary Approaches for Uncovering the Anti-tumor Mechanisms of Chinese Drugs and Natural ProductsView all 5 articles
Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis(MCDA)
Provisionally accepted
- Gansu University of Chinese Medicine, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study employs multi-criteria decision analysis (MCDA) to assess the benefits and risks of combining Fuzheng Yiliu Decoction with chemotherapy for the treatment of non-small cell lung cancer (NSCLC). The objective is to enhance the integration of traditional Chinese medicine with conventional chemotherapy to improve clinical outcomes for NSCLC patients. A comprehensive literature search identified 6 randomized controlled trials (RCTs) that compared chemotherapy alone with chemotherapy combined with Fuzheng Yiliu Decoction. The MCDA model revealed that combination therapy resulted in significantly higher benefit values (72) compared to chemotherapy alone (29). The risk value for combination therapy (56) was slightly higher than that of chemotherapy alone (24), the overall benefit-risk value for combination therapy (68) was notably greater than that of chemotherapy alone (27).Monte Carlo simulation reveals that the difference in total efficacy-risk values between the two treatment modalities is 41 38.73),Furthermore, the probability that the total benefit-risk value of the combination of Fuzheng Yiliu Decoction and chemotherapy for treating NSCLC exceeds that of chemotherapy alone is 81.83%. These findings suggest that combining Fuzheng Yiliu Decoction with chemotherapy enhances therapeutic efficacy and mitigates the adverse side effects of chemotherapy, offering a promising treatment strategy for NSCLC. This study provides valuable insights for improving treatment approaches and clinical decision-making in the management of NSCLC.
Keywords: Fuzheng Yiliu decoction, Non-small cell lung cancer, combined therapy, Multicriteria decision analysis (MCDA), Traditional Chinese Medicine, Clinical decisionmaking
Received: 29 May 2025; Accepted: 27 Aug 2025.
Copyright: © 2025 Ma, Yang, He, Gao, Wang, Yan and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianjun Wu, Gansu University of Chinese Medicine, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.